• HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody

  2026-08-17

  HyperFluor™ 488 Goat Anti-Human IgG (H+L) Antibody supports bright, flexible detection of human IgG across immunofluorescence, Western blotting, flow cytometry, tissue staining, and ELISA. Its main use-case advantage is a direct fluorescent readout for human-serum and cell-based assays, while careful host-species matching keeps vaccine studies analytically valid.

• Anlotinib Hydrochloride in Angiogenesis Assays

  2026-08-17

  Anlotinib hydrochloride provides a practical way to connect receptor-level signaling with endothelial migration, tube formation, and tumor-vascularization readouts. This workflow-focused guide explains assay setup, concentration selection, comparative benchmarking, and troubleshooting for reproducible cancer research.

• EZ Cap™ Cre mRNA (m1Ψ): A Decision Guide

  2026-08-16

  This decision-focused guide explains how EZ Cap™ Cre mRNA (m1Ψ) converts transient mRNA expression into interpretable Cre/loxP experiments. It connects cap chemistry, mRNA handling, delivery design, and extrahepatic assay decisions without conflating carrier performance with recombinase performance.

• Tropisetron: From Receptor Tool to Translational Probe

  2026-08-15

  Tropisetron Hydrochloride is more than a selective 5-HT3 receptor antagonist: its dual receptor profile and emerging OCT2/MATE1 interaction data make it a useful translational probe. This article connects receptor pharmacology, transporter biology, assay design, and practical decision-making for researchers developing mechanistic and pharmacokinetic hypotheses.

• Foretinib: Separating Growth Arrest From Cell Death

  2026-08-14

  Foretinib (GSK1363089) is a multikinase inhibitor whose effects can reflect both cytostatic growth arrest and cell killing. This guide combines its Met and VEGFR pharmacology with a quantitative assay framework for interpreting viability, motility, invasion, and metastasis data.

• Anlotinib Hydrochloride: From Assay to Tumor Biology

  2026-08-14

  Anlotinib hydrochloride connects nanomolar kinase inhibition with measurable angiogenic phenotypes and a cautiously interpreted rare-tumor case. This article explains how to translate receptor, endothelial, pharmacokinetic, and clinical evidence into better cancer research decisions.

• NMDA in Retinal Excitotoxicity Research

  2026-08-13

  NMDA (N-Methyl-D-aspartic acid) provides a direct, controllable way to model receptor-driven calcium stress in retinal and neuronal systems. This workflow connects excitotoxic injury with oxidative stress, ferroptosis readouts, and BMP4-GPX4 neuroprotection experiments.

• From TIL Biology to Better Fluorescence Readouts

  2026-08-13

  A translational perspective on how tumor-microenvironment modulation can improve TIL therapy—and how disciplined fluorescence workflows, including the FITC Goat Anti-Mouse IgG (H+L) Antibody, help convert mechanistic hypotheses into reproducible evidence.

• Anlotinib Hydrochloride: Reliable Assay Workflows

  2026-08-12

  This scenario-based guide explains how Anlotinib hydrochloride supports reproducible endothelial migration, tube-formation, viability, and signaling studies. It connects quantitative product data with practical assay design and outlines when SKU C8688 is a sensible research-use choice.

• GDC-0941 for PI3K/Akt Pathway Assays

  2026-08-12

  GDC-0941 provides a practical way to connect PI3K signaling changes with cancer cell proliferation, apoptosis, and therapy resistance. This workflow translates PI3K/Akt biology into reproducible cell-based assays, including models of trastuzumab-resistant HER2-amplified cancer and liver cancer stem cell phenotypes.

• CTCF, Centromere Function, and Mitotic Fidelity

  2026-08-11

  The reference study uses rapid auxin-inducible degradation to show that CTCF is required for centromere performance, accurate mitosis, and normal post-mitotic nuclear shape. Its experiments distinguish a centromere-maintenance defect from impaired CENP-E recruitment, providing a mechanistic framework for studying chromosome alignment regulation.

• P2RX1-Driven Mitochondrial Apoptosis in Ph+ ALL

  2026-08-11

  Li et al. identify P2RX1 as a regulator of tyrosine kinase inhibitor response in Philadelphia chromosome-positive acute lymphoblastic leukemia, linking purinergic signaling to calcium imbalance, CaMKII activation, PI3K/Akt suppression, and mitochondrial apoptosis. The findings provide a mechanistic framework for studying treatment sensitivity while highlighting the need for validation in primary leukemia models and in vivo systems.

• Cy5 Hydrazide for Carbonyl Labeling Workflows

  2026-08-10

  Cy5 hydrazide enables far-red detection of aldehyde- and ketone-bearing biomolecules in protein, glycoprotein, oligonucleotide, and nanoparticle workflows. Its strongest differentiator is sensitive carbonyl readout without requiring a sulfonated dye, provided the low-solubility reagent is handled with an appropriate DMSO-based preparation and cleanup strategy.

• Glutamine Metabolism in Hepatic Stellate Cells

  2026-08-09

  The 2022 Cell Death and Disease study identifies SIRT4-mediated control of glutamate dehydrogenase as a metabolic brake on hepatic stellate cell activation and liver fibrosis. Its combination of pharmacological, genetic, cellular, and in vivo evidence supports glutamine catabolism as a mechanistically grounded target for antifibrotic research.

• IWR-1-endo: From Pathway Blockade to Cell States

  2026-08-08

  IWR-1-endo is a potent Wnt signaling inhibitor for dissecting β-catenin-dependent biology. This article connects its Axin-complex mechanism with cell-state-resolved assay design inspired by large-scale single-nucleus profiling in atrial fibrillation research.

7878 records 9/526 page Previous Next First page 上5页 678910 下5页 Last page